Quantitative Magnetic Resonance Imaging in Perianal Crohn’s Disease at 1.5 and 3.0 T: A Feasibility Study

Perianal Crohn’s Disease (pCD) is a common manifestation of Crohn’s Disease. Absence of reliable disease measures makes disease monitoring unreliable. Qualitative MRI has been increasingly used for diagnosing and monitoring pCD and has shown potential for assessing response to treatment. Quantitativ...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ali Alyami, Caroline L. Hoad, Christopher Tench, Uday Bannur, Christopher Clarke, Khalid Latief, Konstantinos Argyriou, Alan Lobo, Philip Lung, Rachel Baldwin-Cleland, Kapil Sahnan, Ailsa Hart, Jimmy K. Limdi, John Mclaughlin, David Atkinson, Geoffrey J. M. Parker, James P. B. O’Connor, Ross A. Little, Penny A. Gowland, Gordon W. Moran
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
MT
DWI
T2
DCE
Acceso en línea:https://doaj.org/article/74ba319f25de4b3fae15fcb087fe6c40
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Perianal Crohn’s Disease (pCD) is a common manifestation of Crohn’s Disease. Absence of reliable disease measures makes disease monitoring unreliable. Qualitative MRI has been increasingly used for diagnosing and monitoring pCD and has shown potential for assessing response to treatment. Quantitative MRI sequences, such as diffusion-weighted imaging (DWI), dynamic contrast enhancement (DCE) and magnetisation transfer (MT), along with T2 relaxometry, offer opportunities to improve diagnostic capability. Quantitative MRI sequences (DWI, DCE, MT and T2) were used in a cohort of 25 pCD patients before and 12 weeks after biological therapy at two different field strengths (1.5 and 3 T). Disease activity was measured with the Perianal Crohn’s Disease Activity index (PDAI) and serum C-reactive protein (CRP). Diseased tissue areas on MRI were defined by a radiologist. A baseline model to predict outcome at 12 weeks was developed. No differences were seen in the quantitative MR measured in the diseased tissue regions from baseline to 12 weeks; however, PDAI and CRP decreased. Baseline PDAI, CRP, T2 relaxometry and surgical history were found to have a moderate ability to predict response after 12 weeks of biological treatment. Validation in larger cohorts with MRI and clinical measures are needed in order to further develop the model.